Takayuki Kimura

TL;DR: Data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.

TL;DR: Eribulin exerted significant effects on EMT/MET-related pathway components in human breast cancer cells in vitro and in vivo, consistent with a phenotypic switch from mesenchymal to epithelial states, and corresponding to observed decreases in migration and invasiveness in vitro as well as experimental metastasis in vivo.

TL;DR: It is shown that lenvatinib modulates cancer immunity in the tumor microenvironment by reducing TAMs and, when combined with PD-1 blockade, shows enhanced antitumor activity via the IFN signaling pathway.

TL;DR: It is shown that eribulin induces remodeling of tumor vasculature through a novel antivascular activity in MX‐1 and MDA‐MB‐231 human breast cancer xenograft models, suggesting that Eribulin‐induced remodelling of abnormal tumor vasculation leads to a more functional microenvironment that may reduce the aggressiveness of tumors due to elimination of inner tumor hypoxia.

TL;DR: Lenvatinib has immunomodulatory activity that contributes to the antitumor activity of lenvatinIB and enhances the antitUMor activity in combination treatment with anti‐PD‐1 antibody, and warrants further investigation against advanced HCC.